Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.95 million versus the consensus estimate of $6.64 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.